This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Axsome Therapeutics, Inc.
American Healthcare REIT, Inc.
Eledon Pharmaceuticals, Inc.
Insmed Incorporated
Trevi Therapeutics
Axsome Therapeutics, Inc. AXSM | 0.00 | |
American Healthcare REIT, Inc. AHR | 0.00 | |
Eledon Pharmaceuticals, Inc. ELDN | 0.00 | |
Insmed Incorporated INSM | 0.00 | |
Trevi Therapeutics TRVI | 0.00 |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- BMO Capital analyst Connor Mackay initiated coverage on Insmed Inc (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
- BMO Capital analyst Malcolm Hoffman initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
- Compass Point analyst Rob Simone initiated coverage on American Healthcare REIT Inc (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
- BMO Capital analyst Connor Murphy initiated coverage on Trevi Therapeutics Inc (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
- Rodman & Renshaw analyst Seema Sheoran initiated coverage on Eledon Pharmaceuticals Inc (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.
Considering buying INSM stock? Here’s what analysts think:
Photo via Shutterstock